Abivax announces the successful completion of a reserved oversubscribed capital increase of approximately EUR 60M through the issuance of 1,964,031 shares with a nominal value of EUR 0.01 each, representing 13.34% of its current share capital, at a subscription price of EUR 30.55 per share, and the placement of senior, unsecured bonds convertible into new shares and/or exchangeable for existing shares maturing in July 30, 2026 in aggregate principal amount of EUR 25M.
July 23, 2021
· 25 min read